Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine.

Détails

ID Serval
serval:BIB_71A0CEB8D7A9
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine.
Périodique
Acta Neurochirurgica. Supplement
Auteur(s)
Pirotte B., Goldman S., David P., Wikler D., Damhaut P., Vandesteene A., Salmon L., Brotchi J., Levivier M.
ISSN
0065-1419 (Print)
ISSN-L
0065-1419
Statut éditorial
Publié
Date de publication
1997
Volume
68
Pages
133-138
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
The aim of the present study was to compare the contribution of the labelled tracers [C-11]methionine (Met) and [F-18]-fluorodeoxyglucose (FDG) in positron emission tomography (PET)-guided stereotactic biopsy of non resectable brain lesions. Twenty-five patients underwent combined Met-PET-, FDG-PET- and computerized tomography (CT)- or magnetic resonance (MR)-guided stereotactic biopsy according to a previously described technique for stereotactic FDG-PET. Met-PET and FDG-PET images were analyzed to determine which tracer offers the best information to guide at least one stereotactic biopsy trajectory. Histological diagnosis was obtained in all patients (23 tumours and 2 non-tumorous lesions). All tumours had an area of abnormal Met uptake and were biopsied under PET-guidance. FDG uptake in the tumour was higher than in the grey matter and was used for target selection in 12 of 23 tumours. Eleven of them were located in the basal ganglia or the brainstem. Met was used for target selection in 11 of 23 tumours where there was no FDG uptake or where FDG uptake was equivalent to that of the grey matter. Ten of them were located in the cortex. Two nontumoral lesions had no Met uptake and were biopsied under CT- or MR-guidance only. Forty-three out of 53 stereotactic trajectories obtained in these 25 patients were based on PET-defined targets and had an area of abnormal Met uptake. These trajectories always yielded a diagnosis of tumour. Moreover, all tumorous trajectories had an area of abnormal Met uptake. Finally, all non-diagnostic trajectories (n = 4) were CT/MR-defined because there was no area of abnormal Met uptake. These results suggest that patients who can benefit the most from Met-PET guidance could be selected pre-operatively. In conclusion, this work shows that Met is a good alternative to FDG for target selection in PET-guided stereotactic brain biopsy.
Mots-clé
Adolescent, Adult, Aged, Biopsy/instrumentation, Brain/pathology, Brain/radionuclide imaging, Brain Neoplasms/pathology, Brain Neoplasms/radionuclide imaging, Child, Child, Preschool, Deoxyglucose/analogs & derivatives, Deoxyglucose/diagnostic use, Female, Fluorodeoxyglucose F18, Humans, Magnetic Resonance Imaging/instrumentation, Male, Methionine/diagnostic use, Middle Aged, Reproducibility of Results, Stereotaxic Techniques/instrumentation, Tomography, Emission-Computed/instrumentation, Tomography, X-Ray Computed/instrumentation
Pubmed
Web of science
Création de la notice
20/01/2008 17:35
Dernière modification de la notice
20/08/2019 14:30
Données d'usage